Skip to content

Effects of Supplemental Oxygen Delivered by a Portable Oxygen Concentrator Compared to a Liquid Oxygen Device in COPD

Effects of Supplemental Oxygen Delivered by a Portable Oxygen Concentrator Compared to a Liquid Oxygen Device in Hypoxemic COPD Patients at Rest

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03174210
Enrollment
20
Registered
2017-06-02
Start date
2017-05-02
Completion date
2017-09-15
Last updated
2018-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD, supplemental oxygen, oxygen concentrator

Brief summary

The aim of this study is to investigate the effects of supplemental oxygen on blood oxygenation at rest in Patients with severe to very severe COPD comparing the portable oxygen concentrator (Activox™ 4L) to a liquid continuous oxygen device (Companion®).

Detailed description

It has been proven that supplemental oxygen increases oxygen saturation and reduces dyspnea in hypoxemic COPD Patients. There are different oxygen delivery systems available, some of them operating with liquid oxygen and others by concentrating the ambient air (concentrators). An advantage of the concentrator system is, that there is no refill required, but only a power plug and plug socket, enabling the patient for higher mobility and to be more autonomous. There are only few publications about whether portable oxygen concentrators have a comparable efficiency on oxygen saturation to liquid oxygen devices with continuous flow (LOD) or not. Until now there are no official recommendations about how to convert the oxygen flow rate for LOD (liter per minute) into the corresponding level of the POC. Therefore, we investigate the comparability of the portable oxygen concentrator Activox™ 4L (POC) to a liquid oxygen device (Companion®) in 30 hypoxemic COPD patients at rest. As a baseline assessment, the patients will receive a bodyplethysmography, blood gas analysis without using supplemental oxygen and an evaluation of the diffusion capacity of the lung for CO. The study will be conducted on 2 consecutive days. 15 patients will be randomized into two different groups: First group will start with POC and will continue the following day with LOD; The second group will start with LOD and continue with POC (cross-over design). All patients will use the same oxygen devices during the study assessments (LOD: Companion 1000 (CE 0050), Chart Industries Inc., Garfiel Heights, OH, USA; POC: Activox™ 4L, Inovalabs Inc., Texas, USA). On both days of the study, patients will be connected to one of the two systems via nasal cannula for a total time period of 40 minutes, while the patient remains in a sitting position without talking. The oxygen flow rate starts at 1liter/min (LOD) or Level 1 (POC) and will be increased every 10 minutes to the next higher level until the maximum of 4l/min (LOD) or level 4 (POC) is reached. Blood gases were taken and breathing frequency will be recorded at the end of each Oxygen Level.

Interventions

DEVICEliquid oxygen device (LOD)

This oxygen Supplementation is used in special order

This oxygen Supplementation is used in special order

Sponsors

Schön Klinik Berchtesgadener Land
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

patients will be randomized into two different Groups (prospective cross-over design)

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* COPD patients with hypoxemia at rest (paO2 \< 55 or 60 mmHg, according to the recent supplemental oxygen guidelines \[Hadringe, M., et al., British Thoracic Society guidelines for home oxygen use in adults. Thorax, 2015. 70 Suppl 1: p. i1-43.\] * Participation in an inpatient pulmonary rehabilitation program (Schön Klinik BGL) * Written informed consent

Exclusion criteria

* The Need of more than 4 Liter/min Oxygen at rest to achieve PaO2 \> 55 or 60mmHg * Signs of acute exacerbation * General

Design outcomes

Primary

MeasureTime frameDescription
Difference between LOD and POC in Partial pressure of oxygen levelsafter 10 minutes of each LOD step compared to 10 minutes of each POC stepPO2 values between LOD and POC at comparable Levels of oxygen supply (1liter/minute LOD will be compared to Level 1 of POC until 4liters/Minute LOD to Level 4 of POC)

Secondary

MeasureTime frameDescription
Difference between LOD and POC in Partial pressure of carbon dioxide levelsafter 10 minutes of each LOD step compared to 10 minutes of each POC stepPCO2 values between LOD and POC at comparable Levels of oxygen supply (1liter/minute LOD will be compared to Level 1 of POC until 4liters/Minute LOD to Level 4 of POC)
Change of partial pressure of Oxygen from one POC step to the next stepafter 10 minutes of one POC step compared to after 10 minutes of the next POC stepChange in PO2 values from e.g. POC step 1 to POC step 2, step 2 to 3 etc.
Change of partial pressure of carbon dioxide from one POC step to the next stepafter 10 minutes of one POC step compared to after 10 minutes of the next POC stepChange in PCO2 values between e.g. POC step 1 to POC step 2, step 2 to 3 etc.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026